Advancements in Treatment Landscape for Spondyloarthritis

The chapter explores the evolving treatment options for spondyloarthritis patients, discussing the importance of IL-17 inhibitors and TNF inhibitors in addition to NSAIDs. It highlights the efficacy of various biologic agents in managing extra musculoskeletal manifestations and presents new data on inhibitors like cecacinumab and ixochizumab. The chapter also covers patient case studies, JAK inhibitor efficacy, use of combination biologics, and insights on tapering biologics in sustained remission.